AI Article Synopsis
- Brain gadolinium deposition, first noted in 2014, is acknowledged as a dose-dependent effect of gadolinium-based contrast agents, but its clinical implications remain unclear.
- An electronic survey conducted among 94 radiologists from 30 countries revealed that while 62% have observed gadolinium deposition, most do not include it in reports due to concerns about causing patient anxiety.
- The findings indicate a lack of consensus among radiologists regarding the reporting of gadolinium deposition, highlighting an urgent need for clearer guidelines and understanding of the issue.
Article Abstract
Rationale And Objectives: Brain deposition of gadolinium following the administration of gadolinium-based contrast agents (GBCAs) was initially reported in 2014. Gadolinium deposition is now recognized as a dose-dependent consequence of exposure. The potential clinical implications are not yet understood. The purpose of this study was to determine radiologists' reporting practices in response to gadolinium deposition.
Materials And Methods: An electronic survey querying radiologists' practices regarding gadolinium deposition was distributed by Radiopaedia.org from November-December 2015.
Results: Our study sample included 94 total respondents (50% academic; 27% private practice; 23% hybrid) from 30 different countries (USA 18%). Fifty-seven (62%) radiologists had observed brain gadolinium deposition on MRI brain studies howerver more than half of these (30 of 57) reported detecting dentate T1 shortening only rarely (<1/month). Among respondents, 58% (52 of 89) do not or would not include the finding in the radiology report; only 12 (13%) report the finding in the impression of their reports. The most common reason for not reporting gadolinium deposition was the risk of provoking unnecessary patient anxiety (29%, 20 of 70). Recent data on gadolinium deposition has led to a reported practice change in 24 of 87 (28%) of respondents.
Conclusion: Recognition of, and attitudes toward, brain gadolinium deposition were inconsistent in this worldwide sample. Most surveyed radiologists do not routinely report dentate T1shortening as a marker of gadolinium deposition. Fear of provoking patient/clinician anxiety and an incomplete understanding of the implications of gadolinium deposition contribute to inconsistencies in reporting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1067/j.cpradiol.2018.02.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: In proton radiotherapy, the steep dose deposition profile near the end of the proton's track, the Bragg peak, ensures a more conformed deposition of dose to the tumor region when compared with conventional radiotherapy while reducing the probability of normal tissue complications. However, uncertainties, as in the proton range, patient geometry, and positioning pose challenges to the precise and secure delivery of the treatment plan (TP). In vivo range determination and dose distribution are pivotal for mitigation of uncertainties, opening the possibility to reduce uncertainty margins and for adaptation of the TP.
View Article and Find Full Text PDFLong-term effects of linear versus macrocyclic GBCAs on gene expression in the central nervous system of mice.
Eur Radiol Exp
January 2025
Laboratory of Molecular Imaging, Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Background: We examined chronic gadolinium retention impact on gene expression in the mouse central nervous system (CNS) after injection of linear or macrocyclic gadolinium-based contrast agents (GBCAs).
Methods: From 05/2022 to 07/2023, 36 female mice underwent weekly intraperitoneal injections of gadodiamide (2.5 mmol/kg, linear), gadobutrol (2.
Case Report: A missed diagnosis of cardiac amyloidosis using echocardiography due to immunoglobulin light chain amyloidosis with normal wall thickness in the early stage.
Front Cardiovasc Med
December 2024
National Key Laboratory for Innovation and Transformation of Luobing Theory, Jinan, China.
Background: Cardiac amyloidosis (CA) is a challenging diagnosis, particularly when the classic signs, such as increased wall thickness in a non-dilated left ventricle (LV), are absent. This makes the diagnosis more difficult in patients with normal LV wall thickness. We present a case of CA without increased wall thickness and without the characteristic granular sparkling echotexture in a non-dilated LV.
View Article and Find Full Text PDFElectrochemical Method for the Design of New Possible Gadolinium-Based Contrast Agents.
Nanomaterials (Basel)
December 2024
Laboratory of Applied Electrochemistry, Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi, 19, 20133 Milan, Italy.
Magnetic resonance imaging (MRI) is a technique that employs strong magnetic fields and radio frequencies to generate detailed images of the body's interior. In oncology patients, gadolinium-based contrast agents (GBCAs) are frequently administered to enhance the visualization of tumors. Those contrast agents are gadolinium chelates, characterized by high stability that prevents the release of the toxic gadolinium ion into the body.
View Article and Find Full Text PDFArticle Synopsis
- The Gadolinium Research and Education Committee (GREC) monitors and improves the safety and effectiveness of gadolinium-based contrast agents (GBCAs) used in MRI, emphasizing the need for alternatives and careful dosage.
- GBCAs are crucial for enhancing MRI images and clinical decision-making, and guidelines recommend their use only when necessary and at the lowest effective dose.
- The article discusses evaluating GBCA use in terms of cost-effectiveness, environmental impact, and the benefits of emerging next-generation GBCAs, which promise better stability and effectiveness at reduced doses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!